B8.051 Germ Cell Tumors Flashcards
epidemiology of testicular cancer
males between age 15-45 years
<1% of all cancers in men
highest risk in scandinavia and switzerland, lowest in asia and africa
risk factor for testicular cancers
cryptorchidism: 3-5x klinefelter's syndrome (XXY) infertility: 1-2x family history: sibling history is 8-10x prior history of testicular cancer increases risk of contralateral tumor HIV
lymphatic drainage of testicle region
scrotal skin drains to superficial inguinal nodes
testis drain to lumbar lymphatic nodes (para aortic)
clinical presentation of testicular cancer
painless testicular swelling (60-70% of patients)
heavy sensation or testicular discomfort (30%)
acute pain is rare
symptoms or signs of metastatic testicular disease
10% of patients
- nausea, vomiting, abdominal pain (retroperitoneal LN)
- cough, dyspnea (lung mets)
- neck mass (supraclavicular LN)
- bony pain (osseous metastases) +/- radiculopathy
ddx of tender testicular mass
torsion
orchitis
epididymitis
ddx of nontender testicular mass
hydocele: trans illumination +
varicocele: ‘bag of worms’ on palpation
inguinal hernia: indirect, extends to inguinal ring
spermatocele
malignancy: testicular cancer, lymphomas
common course of testicular cancer
painless testicular mass
course antibiotics for 2-4 weeks
testicular US
radical inguinal orchiectomy
imaging studies for evaluating testicular cancer
testicular US
-extremely sensitive in evaluating testicular masses (nearly 100%)
CT scan (chest, abdomen, pelvis)
-to determine adenopathy and visceral involvement
tumor markers of testicular cancer
AFP
B-HCG
LDH
AFP in testicular cancer
synthesized by fetal yolk sac, liver, and intestines
half life of 5-7 days
elevated in yolk sac tumors and teratomas
false elevations of AFP
hepatic dysfunction
B-HCG in testicular cancer
secreted by syncitiotrophoblastic cells
half life 1-1.5 days
elevated in seminomas and choriocarcinomas
false elevations of B-HCG
tumor lysis after chemo
treatment related hypogonadism
marijuana use
presence of heterophile antibodies
LDH in testicular cancer
nonspecific tumor marker
marker of overall tumor burden, growth, and overall proliferation
elevated in 60-80% of patients with advanced disease